

# Clyde W Yancy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1087034/publications.pdf>

Version: 2024-02-01

237  
papers

19,307  
citations

38742

50  
h-index

12272

133  
g-index

239  
all docs

239  
docs citations

239  
times ranked

25117  
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction. <i>Circulation</i> , 2010, 121, 586-613.	1.6	3,508
2	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. <i>Circulation</i> , 2013, 128, 1810-1852.	1.6	2,807
3	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. <i>Circulation</i> , 2017, 136, e137-e161.	1.6	2,130
4	COVID-19 and African Americans. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1891.	7.4	1,609
5	Systolic Blood Pressure at Admission, Clinical Characteristics, and Outcomes in Patients Hospitalized With Acute Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 2217.	7.4	854
6	Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2015, 131, 269-279.	1.6	763
7	Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2476-2486.	2.8	671
8	Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality. <i>JAMA Cardiology</i> , 2020, 5, 751.	6.1	471
9	Association of the Hospital Readmissions Reduction Program Implementation With Readmission and Mortality Outcomes in Heart Failure. <i>JAMA Cardiology</i> , 2018, 3, 44.	6.1	346
10	Prediction of 30-Day All-Cause Readmissions in Patients Hospitalized for Heart Failure. <i>JAMA Cardiology</i> , 2017, 2, 204.	6.1	249
11	Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. <i>American Heart Journal</i> , 2011, 161, 1024-1030.e3.	2.7	196
12	Recalibrating the Use of Race in Medical Research. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 623.	7.4	187
13	Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure. <i>Circulation: Heart Failure</i> , 2018, 11, e004646.	3.9	134
14	Trends in 30-Day Readmission Rates for Patients Hospitalized With Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	127
15	Racial and Ethnic Differences in Presentation and Outcomes for Patients Hospitalized With COVID-19: Findings From the American Heart Association's COVID-19 Cardiovascular Disease Registry. <i>Circulation</i> , 2021, 143, 2332-2342.	1.6	113
16	10-Year Risk Equations for Incident Heart Failure in the General Population. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2388-2397.	2.8	107
17	Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	104
18	Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake. <i>European Heart Journal</i> , 2020, 41, 3363-3373.	2.2	103

#	ARTICLE	IF	CITATIONS
19	Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 305-309.	4.1	101
20	Intracoronary Gene Transfer of Adenylyl Cyclase 6 in Patients With Heart Failure. <i>JAMA Cardiology</i> , 2016, 1, 163.	6.1	100
21	Incremental Value of Clinical Data Beyond Claims Data in Predicting 30-Day Outcomes After Heart Failure Hospitalization. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 60-67.	2.2	96
22	Hypertension, Obesity, Diabetes, and Heart Failure-Free Survival. <i>JACC: Heart Failure</i> , 2016, 4, 911-919.	4.1	96
23	Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2018, 3, 288.	6.1	93
24	Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure. <i>Circulation</i> , 2016, 134, 517-526.	1.6	90
25	Kidney Function and Outcomes in Patients Hospitalized With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 330-343.	2.8	90
26	Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure. <i>JAMA Cardiology</i> , 2016, 1, 714.	6.1	89
27	The Hospital Readmission Reduction Program Is Associated With Fewer Readmissions, More Deaths. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1931-1934.	2.8	79
28	Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 948.	6.1	77
29	Trial characteristics associated with under-enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: a systematic review. <i>European Journal of Heart Failure</i> , 2021, 23, 15-24.	7.1	74
30	Home-Time After Discharge Among Patients Hospitalized With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2643-2652.	2.8	72
31	Population Risk Prediction Models for Incident Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 438-447.	3.9	69
32	Association of 30-Day Readmission Metric for Heart Failure Under the Hospital Readmissions Reduction Program With Quality of Care and Outcomes. <i>JACC: Heart Failure</i> , 2016, 4, 935-946.	4.1	68
33	Rhythm Control Versus Rate Control in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction: Insights From Get With The Guidelines Heart Failure. <i>Journal of the American Heart Association</i> , 2019, 8, e011560.	3.7	68
34	Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 314.	7.4	68
35	Short- and Long-term Rehospitalization and Mortality for Heart Failure in 4 Racial/Ethnic Populations. <i>Journal of the American Heart Association</i> , 2014, 3, e001134.	3.7	67
36	World Heart Federation Roadmap for Heart Failure. <i>Global Heart</i> , 2019, 14, 197.	2.3	67

#	ARTICLE	IF	CITATIONS
37	Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 39.	7.4	65
38	Sex Differences in Heart Failure. <i>Journal of Cardiac Failure</i> , 2022, 28, 477-498.	1.7	62
39	In-hospital worsening heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 1104-1113.	7.1	60
40	Heart Rate at Hospital Discharge in Patients With Heart Failure Is Associated With Mortality and Rehospitalization. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	60
41	Multiparametric Cardiac Magnetic Resonance Imaging Can Detect Acute Cardiac Allograft Rejection After Heart Transplantation. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 1632-1641.	5.3	60
42	Coronavirus Disease 2019 (COVID-19) and the Heart: Is Heart Failure the Next Chapter?. <i>JAMA Cardiology</i> , 2020, 5, 1216.	6.1	59
43	The Prognostic Significance of Heart Rate in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in Sinus Rhythm. <i>JACC: Heart Failure</i> , 2013, 1, 488-496.	4.1	58
44	Association of Variants in <i>BAG3</i> With Cardiomyopathy Outcomes in African American Individuals. <i>JAMA Cardiology</i> , 2018, 3, 929.	6.1	57
45	Medication dosing for heart failure with reduced ejection fraction: opportunities and challenges. <i>European Journal of Heart Failure</i> , 2019, 21, 286-296.	7.1	57
46	The Hospital Readmissions Reduction Program. <i>JACC: Heart Failure</i> , 2020, 8, 1-11.	4.1	57
47	Worldwide disparities in cardiovascular disease: Challenges and solutions. <i>International Journal of Cardiology</i> , 2016, 202, 433-440.	1.7	55
48	Impact of Body Mass Index on Heart Failure by Race/Ethnicity From the Get With The Guidelines Heart Failure (GWTG-HF) Registry. <i>JACC: Heart Failure</i> , 2018, 6, 233-242.	4.1	55
49	Characteristics, Treatments, and Outcomes of Hospitalized Heart Failure Patients Stratified by Etiologies of Cardiomyopathy. <i>JACC: Heart Failure</i> , 2015, 3, 906-916.	4.1	54
50	Academic Medicine and Black Lives Matter. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 435.	7.4	53
51	Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2015, 17, 1022-1031.	7.1	52
52	Factors Associated With and Prognostic Implications of Cardiac Troponin Elevation in Decompensated Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2017, 2, 136.	6.1	50
53	Trends in Hospice Discharge and Relative Outcomes Among Medicare Patients in the Get With The Guidelines Heart Failure Registry. <i>JAMA Cardiology</i> , 2018, 3, 917.	6.1	50
54	Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	46

#	ARTICLE	IF	CITATIONS
55	Association of the New Peer Groupâ€œStratified Method With the Reclassification of Penalty Status in the Hospital Readmission Reduction Program. JAMA Network Open, 2019, 2, e192987.	5.9	42
56	Race/Ethnic Differences in Outcomes Among Hospitalized Medicare Patients With Heart Failure and Preserved Ejection Fraction. JACC: Heart Failure, 2017, 5, 483-493.	4.1	41
57	Cardiology and COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 1131.	7.4	41
58	G-Protein Beta-3 Subunit Genotype Predicts Enhanced Benefit of Fixed-Dose Isosorbide Dinitrate and Hydralazine. JACC: Heart Failure, 2014, 2, 551-557.	4.1	40
59	Overcoming Lack of Diversity in Cardiovascular Clinical Trials. Circulation, 2019, 140, 1690-1692.	1.6	39
60	2016 ESC and ACC/AHA/HFSA heart failure guideline update â€œ what is new and why is it important?. Nature Reviews Cardiology, 2016, 13, 623-628.	13.7	38
61	High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial. American Heart Journal, 2018, 202, 97-103.	2.7	38
62	Temporal Trends and Factors Associated With Cardiac Rehabilitation Participation Among Medicare Beneficiaries With Heart Failure. JACC: Heart Failure, 2021, 9, 471-481.	4.1	38
63	Association of Hospital Performance Based on 30-Day Risk-Standardized Mortality Rate With Long-term Survival After Heart Failure Hospitalization. JAMA Cardiology, 2018, 3, 489.	6.1	37
64	A common variant alters SCN5Aâ€™miR-24 interaction and associates with heart failure mortality. Journal of Clinical Investigation, 2018, 128, 1154-1163.	8.2	34
65	Heart Failure with Preserved Ejection Fraction in Women. Heart Failure Clinics, 2019, 15, 9-18.	2.1	33
66	Clinical Effectiveness of CRT and ICD Therapy in Heart Failure Patients by Racial/Ethnic Classification. Journal of the American College of Cardiology, 2014, 64, 797-807.	2.8	32
67	Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease. Journal of the American Heart Association, 2017, 6, .	3.7	32
68	Association of the Affordable Care Actâ€™s Medicaid Expansion With Care Quality and Outcomes for Low-Income Patients Hospitalized With Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004729.	2.2	31
69	Association of Arterial Pulse Pressure With Long-Term Clinical Outcomes in Patients With Heart Failure. JACC: Heart Failure, 2016, 4, 42-49.	4.1	30
70	Vaccination Trends in Patients With Heart Failure. JACC: Heart Failure, 2018, 6, 844-855.	4.1	30
71	Representativeness of a Heart Failure Trial by Race and Sex. JACC: Heart Failure, 2019, 7, 980-992.	4.1	30
72	Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure. Journal of Cardiac Failure, 2021, 27, 826-836.	1.7	30

#	ARTICLE	IF	CITATIONS
73	Diversity in Medical Schoolsâ€™ Need for a New Bold Approach. JAMA - Journal of the American Medical Association, 2021, 325, 31.	7.4	30
74	Health-related quality of life in mechanical circulatory support: Development of a new conceptual model and items for self-administration. Journal of Heart and Lung Transplantation, 2015, 34, 1292-1304.	0.6	29
75	Clinical Effectiveness of Hydralazineâ€™Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry. Circulation: Heart Failure, 2016, 9, e002444.	3.9	29
76	Preparedness and Mutuality Affect Quality of Life for Patients With Mechanical Circulatory Support and Their Caregivers. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e004414.	2.2	29
77	Prognostic Value of Myocardial Extracellular Volume Fraction and T2-mapping in Heart Transplant Patients. JACC: Cardiovascular Imaging, 2020, 13, 1521-1530.	5.3	29
78	Nitrate Therapy for Heart Failure. JACC: Heart Failure, 2013, 1, 183-191.	4.1	28
79	Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women. Circulation: Heart Failure, 2016, 9, e002630.	3.9	28
80	Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization. Circulation, 2017, 135, 2077-2080.	1.6	28
81	Patient Perceptions and Familiarity With Medical Therapy for Heart Failure. JAMA Cardiology, 2020, 5, 292.	6.1	28
82	Trends in the Prevalence of Self-reported Heart Failure by Race/Ethnicity and Age From 2001 to 2016. JAMA Cardiology, 2020, 5, 1425.	6.1	28
83	Endpoints in Heart Failure Drug Development. JACC: Heart Failure, 2020, 8, 429-440.	4.1	28
84	Impaired Cardiac Function and Cognitive Brain Aging. Canadian Journal of Cardiology, 2017, 33, 1587-1596.	1.7	25
85	Clinical Characteristics and Outcomes of Adults With a History of Heart Failure Hospitalized for COVID-19. Circulation: Heart Failure, 2021, 14, e008354.	3.9	25
86	Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention. Journal of the American Heart Association, 2014, 3, e001098.	3.7	24
87	Temporal Trends and Variation in Early Scheduled Follow-Up After a Hospitalization for Heart Failure. Circulation: Heart Failure, 2016, 9, .	3.9	24
88	Cluster-Randomized Trial of Personalized Site Performance Feedback in Get With The Guidelines-Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 421-427.	2.2	22
89	Guideline-Appropriate Care and In-Hospital Outcomes in Patients With Heart Failure in Teaching and Nonteaching Hospitals. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 757-766.	2.2	22
90	Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation, 2019, 140, 2108-2118.	1.6	22

#	ARTICLE	IF	CITATIONS
91	Pre-Ventricular Assist Device Palliative Care Consultation: A Qualitative Analysis. <i>Journal of Pain and Symptom Management</i> , 2019, 57, 100-107.	1.2	22
92	Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice. <i>JAMA Cardiology</i> , 2021, 6, 267.	6.1	22
93	Sex-Based Differences in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1530-1541.	2.8	22
94	Usefulness of Coronary Artery Calcium to Predict Heart Failure With Preserved Ejection Fraction in Men Versus Women (from the Multi-Ethnic Study of Atherosclerosis). <i>American Journal of Cardiology</i> , 2017, 120, 1847-1853.	1.6	21
95	Heart Failure and Sudden Cardiac Death. <i>Cardiac Electrophysiology Clinics</i> , 2017, 9, 709-723.	1.7	21
96	Medicare Expenditures by Race/Ethnicity After Hospitalization for Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2018, 6, 388-397.	4.1	21
97	Pediatric Heart Transplantation: Transitioning to Adult Care (TRANSIT): Feasibility of a Pilot Randomized Controlled Trial. <i>Journal of Cardiac Failure</i> , 2019, 25, 948-958.	1.7	21
98	Improving cardiovascular clinical trials conduct in the United States: Recommendation from clinicians, researchers, sponsors, and regulators. <i>American Heart Journal</i> , 2015, 169, 305-314.	2.7	20
99	Early Ambulation Among Hospitalized Heart Failure Patients Is Associated With Reduced Length of Stay and 30-Day Readmissions. <i>Circulation: Heart Failure</i> , 2018, 11, e004634.	3.9	20
100	Association of State Medicaid Expansion With Rate of Uninsured Hospitalizations for Major Cardiovascular Events, 2009-2014. <i>JAMA Network Open</i> , 2018, 1, e181296.	5.9	20
101	Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials. <i>JAMA Cardiology</i> , 2022, 7, 540.	6.1	20
102	Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	19
103	Contemporary Approaches to Patients with Heart Failure. <i>Cardiology Clinics</i> , 2017, 35, 261-271.	2.2	19
104	Risk-Based Approach for the Prediction and Prevention of Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e007761.	3.9	19
105	Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2021, 9, 876-886.	4.1	19
106	Association of post-discharge specialty outpatient visits with readmissions and mortality in high-risk heart failure patients. <i>American Heart Journal</i> , 2019, 212, 101-112.	2.7	18
107	Improving Care for Heart Failure With Reduced Ejection Fraction—A Potential Polypill-Based Strategy. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2259.	7.4	18
108	Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006645.	3.9	18

#	ARTICLE	IF	CITATIONS
109	Availability and Use of Shared Data From Cardiometabolic Clinical Trials. <i>Circulation</i> , 2018, 137, 938-947.	1.6	17
110	Long-term outcomes for heart failure patients with and without diabetes: From the Get With The Guidelinesâ€“Heart Failure Registry. <i>American Heart Journal</i> , 2019, 211, 1-10.	2.7	17
111	Predictive Accuracy of Heart Failure-Specific Risk Equations in an Electronic Health Record-Based Cohort. <i>Circulation: Heart Failure</i> , 2020, 13, e007462.	3.9	17
112	Evaluation of Risk-Adjusted Home Time After Hospitalization for Heart Failure as a Potential Hospital Performance Metric. <i>JAMA Cardiology</i> , 2021, 6, 169.	6.1	17
113	Heart Failureâ€“A New Phenotype Emerges. <i>JAMA Cardiology</i> , 2016, 1, 507.	6.1	16
114	Trends in the Use of Guideline-Directed Therapies Among Dialysis Patients Hospitalized With Systolic Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 649-661.	4.1	16
115	Association of Electronic Health Record Use With Quality of Care and Outcomes in Heart Failure: An Analysis of Get With The Guidelinesâ€“Heart Failure. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	16
116	Heart Failure Risk Distribution and Trends in the United States Population, NHANES 1999-2016. <i>American Journal of Medicine</i> , 2021, 134, e153-e164.	1.5	16
117	Optimizing the Potential for Telehealth in Cardiovascular Care (in the Era of COVID-19): Time Will Tell. <i>American Journal of Medicine</i> , 2021, 134, 945-951.	1.5	16
118	Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes. <i>JACC: Heart Failure</i> , 2022, 10, 198-210.	4.1	16
119	Heart failure quality of care and in-hospital outcomes during the COVID-19 pandemic: findings from the Get With The Guidelinesâ€“Heart Failure registry. <i>European Journal of Heart Failure</i> , 2022, 24, 1117-1128.	7.1	16
120	Fibroblast Growth Factor-23, Heart Failure Risk, and Renin-Angiotensin-Aldosterone-System Blockade in Hypertension: The MESA Study. <i>American Journal of Hypertension</i> , 2019, 32, 18-25.	2.0	15
121	Strict Versus Lenient Versus Poor Rate Control Among Patients With Atrial Fibrillation and Heart Failure (from the Get With The Guidelines â€“ Heart Failure Program). <i>American Journal of Cardiology</i> , 2020, 125, 894-900.	1.6	15
122	Trends in Place of Death for Cardiovascular Mortality Related to Heart Failure in the United States From 2003 to 2017. <i>Circulation: Heart Failure</i> , 2020, 13, e006587.	3.9	15
123	Coronavirus Disease-2019 and Heart Failure: A Scientific Statement From the Heart Failure Society of America. <i>Journal of Cardiac Failure</i> , 2022, 28, 93-112.	1.7	15
124	Reproducibility and observer variability of tissue phase mapping for the quantification of regional myocardial velocities. <i>International Journal of Cardiovascular Imaging</i> , 2016, 32, 1227-1234.	1.5	14
125	Reassessing Phase II Heart Failure Clinical Trials. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	14
126	Pediatric Heart Transplantation: Transitioning to Adult Care (TRANSIT): Baseline Findings. <i>Pediatric Cardiology</i> , 2018, 39, 354-364.	1.3	14



#	ARTICLE	IF	CITATIONS
127	Cardiac Structureâ€“Function MRI in Patients After Heart Transplantation. Journal of Magnetic Resonance Imaging, 2019, 49, 678-687.	3.4	14
128	Primer on Biomarker Discovery in Cardio-Oncology. JACC: CardioOncology, 2020, 2, 379-384.	4.0	14
129	Association of Dual Eligibility for Medicare and Medicaid With Heart Failure Quality and Outcomes Among Get With The Guidelinesâ€“Heart Failure Hospitals. JAMA Cardiology, 2021, 6, 791.	6.1	14
130	Extracellular Volume Fraction Is More Closely Associated With Altered Regional Left Ventricular Velocities Than Left Ventricular Ejection Fraction in Nonischemic Cardiomyopathy. Circulation: Cardiovascular Imaging, 2015, 8, .	2.6	13
131	Timing of Postdischarge Followâ€“Up and Medication Adherence Among Patients With Heart Failure. Journal of the American Heart Association, 2018, 7, .	3.7	13
132	A Hospital Level Analysis of 30-Day Readmission Performance for Heart Failure Patients and Long-Term Survival: Findings from Get With The Guidelines-Heart Failure. American Heart Journal, 2018, 200, 127-133.	2.7	13
133	Quality of Care and Outcomes Among Medicare Advantage vs Fee-for-Service Medicare Patients Hospitalized With Heart Failure. JAMA Cardiology, 2020, 5, 1349.	6.1	13
134	Economic Evaluation of Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure With Reduced Ejection Fraction. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e007094.	2.2	13
135	Strokes associated with left ventricular assist devices. Journal of Cardiac Surgery, 2018, 33, 578-583.	0.7	12
136	Impact of an Expanded Hospital Recognition Program for Heart Failure Quality of Care. Journal of the American Heart Association, 2014, 3, e000950.	3.7	11
137	The Uncertainty of Sodium Restriction inâ€“Heart Failure. JACC: Heart Failure, 2016, 4, 39-41.	4.1	11
138	Impact of Current Versus Previous Cardiac Resynchronization Therapy Guidelines on the Proportion of Patients With Heartâ€“Failure Eligible for Therapy. JACC: Heart Failure, 2017, 5, 388-392.	4.1	11
139	Incorporating Patient and Caregiver Experiences Into Cardiovascular Clinical Trial Design. JAMA Cardiology, 2017, 2, 1263.	6.1	11
140	Sodium Restriction in Heart Failure: Too Much Uncertaintyâ€“Do the Trials. JAMA Internal Medicine, 2018, 178, 1700.	5.1	11
141	Stopping medication for heart failure with improved ejection fraction. Lancet, The, 2019, 393, 8-10.	13.7	11
142	Role of Angiotensin Receptor-Nepriylsin Inhibition in Heart Failure. Current Atherosclerosis Reports, 2016, 18, 48.	4.8	10
143	Distribution in Place of Death for <sc>COVID</sc>â€“19â€“Related Mortality in the United States. Journal of the American Geriatrics Society, 2020, 68, 1917-1918.	2.6	10
144	Cardiac transplantation outcomes in patients with amyloid cardiomyopathy. American Heart Journal, 2021, 236, 13-21.	2.7	10

#	ARTICLE	IF	CITATIONS
145	Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e021459.	3.7	10
146	Is the affordable care act medicaid expansion associated with receipt of heart failure guideline-directed medical therapy by race and ethnicity?. <i>American Heart Journal</i> , 2022, 244, 135-148.	2.7	10
147	Prescription of Guideline-Recommended Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy Among Patients Hospitalized With Heart Failure and Varying Degrees of Renal Function. <i>American Journal of Cardiology</i> , 2017, 119, 886-892.	1.6	9
148	Universal Definition and Classification of Heart Failure: Is It universal? Does It Define Heart Failure?. <i>Journal of Cardiac Failure</i> , 2021, 27, 509-511.	1.7	9
149	Development and Validation of a Long-Term Incident Heart Failure Risk Model. <i>Circulation Research</i> , 2022, 130, 200-209.	4.5	9
150	Strategies for early detection of cardiotoxicities from anticancer therapy in adults: evolving imaging techniques and emerging serum biomarkers. <i>Future Oncology</i> , 2015, 11, 2093-2103.	2.4	8
151	COVID-19 and Katrina: recalcitrant racial disparities. <i>European Heart Journal</i> , 2020, 41, 3390-3393.	2.2	8
152	Temporal trends in risk profiles among patients hospitalized for heart failure. <i>American Heart Journal</i> , 2021, 232, 154-163.	2.7	8
153	New Blood Pressure "Lowering Targets" Finding Clarity. <i>JAMA Cardiology</i> , 2017, 2, 719.	6.1	7
154	Evaluating Readmission "Need for More Clarity on Methods" Reply. <i>JAMA Cardiology</i> , 2018, 3, 265.	6.1	7
155	Ventricular Assist Device Driveline Dressing-Change Protocols: A Need for Standardization. A Report from the SimVAD Investigators. <i>Journal of Cardiac Failure</i> , 2019, 25, 695-697.	1.7	7
156	Outcomes and cost among Medicare beneficiaries hospitalized for heart failure assigned to accountable care organizations. <i>American Heart Journal</i> , 2020, 226, 13-23.	2.7	7
157	Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT). <i>American Journal of Cardiology</i> , 2020, 125, 1655-1660.	1.6	7
158	Association of the V122I Transthyretin Amyloidosis Genetic Variant With Cardiac Structure and Function in Middle-aged Black Adults. <i>JAMA Cardiology</i> , 2021, 6, 718.	6.1	7
159	Risk-Based Intensive Blood Pressure Lowering and Prevention of Heart Failure: A SPRINT Post Hoc Analysis. <i>Hypertension</i> , 2021, 78, 1742-1749.	2.7	7
160	Health-Related Quality of Life in Older Patients With Advanced Heart Failure: Findings From the SUSTAIN-T Study. <i>Journal of the American Heart Association</i> , 2022, 11, e024385.	3.7	7
161	Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1420-1423.	2.8	6
162	Consequences of Reductions in Hospital Readmissions. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1933.	7.4	6

#	ARTICLE	IF	CITATIONS
163	Association Between Neighborhood-Level Poverty and Incident Atrial Fibrillation: a Retrospective Cohort Study. <i>Journal of General Internal Medicine</i> , 2022, 37, 1436-1443.	2.6	6
164	Race/Ethnicity-Based Outcomes in Cardiovascular Medicine. <i>JAMA Cardiology</i> , 2017, 2, 1313.	6.1	5
165	Targeting the Correct Population When Designing Transitional Care Programs for Medicare Patients Hospitalized With Heart Failure. <i>JAMA Cardiology</i> , 2017, 2, 1274.	6.1	5
166	The Current Landscape of Atrial Fibrillation and Atrial Flutter Clinical Trials. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 944-954.	3.2	5
167	PARAGON-HF Clinical Trial Eligibility in a Population of Patients Hospitalized With Heart Failure. <i>Journal of Cardiac Failure</i> , 2019, 25, 1009-1011.	1.7	5
168	Adrenergic Polymorphisms and Survival in African Americans With Heart Failure: Results From A-HeFT. <i>Journal of Cardiac Failure</i> , 2019, 25, 553-560.	1.7	5
169	Glycated Hemoglobin and Outcomes of Heart Failure (from Get With the Guidelines-Heart Failure). <i>American Journal of Cardiology</i> , 2019, 123, 618-626.	1.6	5
170	Reporting Genetic Markers and the Social Determinants of Health in Clinical Cardiovascular Research: It Is Time to Recalibrate the Use of Race. <i>JAMA Cardiology</i> , 2021, 6, 400.	6.1	5
171	Reimagining educational equity through strategic alliance partnerships in response to the USA STEM-M diversity gap. <i>Health Promotion International</i> , 2022, 37, .	1.8	5
172	Contemporary Rates of Hospitalization for Heart Failure in Young and Middle-Aged Adults in a Diverse US State. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e007014.	2.2	5
173	Identifying Treatments for Stage C2 Heart Failure. <i>JAMA Cardiology</i> , 2022, 7, 34.	6.1	5
174	Affirming and Nurturing Students' Cultural Wealth to Enhance Self-efficacy: Examination of Urban High School Students' Lived Experiences in a STEM-Medicine Pipeline Program. <i>Urban Education</i> , 0, , 004208592110738.	1.8	5
175	Blood Pressure and Glycemic Control Among Ambulatory US Adults With Heart Failure: National Health and Nutrition Examination Survey 2001 to 2018. <i>Circulation: Heart Failure</i> , 2022, 15, 101161CIRCHEARTFAILURE121009229.	3.9	5
176	Replacing Race With Social Determinants of Health in Risk Prediction: Getting It Right. <i>JAMA Cardiology</i> , 2022, 7, 856.	6.1	5
177	Cardiovascular Disease Disparities. <i>JAMA Cardiology</i> , 2018, 3, 1183.	6.1	4
178	Buffer or Suffer. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004351.	2.2	4
179	Impediments to Implementing Guideline-Directed Medical Therapies. <i>JAMA Cardiology</i> , 2019, 4, 830.	6.1	4
180	Racial Differences and Temporal Obesity Trends in Heart Failure with Preserved Ejection Fraction. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 1309-1318.	2.6	4

#	ARTICLE	IF	CITATIONS
181	United Network for Organ Sharing 2018 Heart Transplant Reallocation Policy. <i>JAMA Cardiology</i> , 2021, 6, 168.	6.1	4
182	Is the Left Ventricular Ejection Fraction Measurement Still Preeminent?â€”New Measures to Quantify Subclinical Systolic Dysfunction. <i>JAMA Cardiology</i> , 2021, 6, 521.	6.1	4
183	The Journey Toward Health Equity: Are We Nearing an Abyss or Ascending a Peak?. <i>Circulation</i> , 2021, 143, 2327-2328.	1.6	4
184	Preventable Deaths From Heart Disease and Stroke Among Racial and Ethnic Minorities in the United States. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007835.	2.2	4
185	Systematic examination of a heart failure risk prediction tool: The pooled cohort equations to prevent heart failure. <i>PLoS ONE</i> , 2020, 15, e0240567.	2.5	4
186	Fibroblast Growth Factor-23 and Subclinical Markers of Cardiac Dysfunction: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. <i>American Heart Journal</i> , 2021, 245, 10-10.	2.7	4
187	Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure. <i>Journal of Cardiac Failure</i> , 2022, 28, 554-563.	1.7	4
188	Disparate Care for Acute Myocardial Infarction. <i>Circulation</i> , 2014, 130, 632-633.	1.6	3
189	Claims Data to Ascertain Clinical Events. <i>JAMA Cardiology</i> , 2017, 2, 758.	6.1	3
190	The New Hypertension Guidelines. <i>JAMA Cardiology</i> , 2018, 3, 581.	6.1	3
191	Data Sharingâ€”The Time Has (Not Yet?) Come. <i>JAMA Cardiology</i> , 2018, 3, 797.	6.1	3
192	Profile of Patients Hospitalized for Heart Failure Who Leave Against Medical Advice. <i>Journal of Cardiac Failure</i> , 2021, 27, 747-755.	1.7	3
193	An Expanded Heart Failure Indication for Sacubitril/Valsartan. <i>JAMA Cardiology</i> , 2021, 6, 1357.	6.1	3
194	Relationship between Hospital 30â€”Day Mortality Rates for Heart Failure and Patterns of Early Inpatient Comfort Care. <i>Journal of Hospital Medicine</i> , 2018, 13, 170-176.	1.4	3
195	Change the Name of the Blalock-Taussig Shunt to Blalock-Thomas-Taussig Shunt. <i>JAMA Surgery</i> , 2021, , .	4.3	3
196	Tipping the scale toward a more accurate and equitable assessment of heart failure with reduced ejection fraction pharmacotherapy eligibility: a call to incorporate cystatin C in estimating glomerular filtration rate. <i>European Journal of Heart Failure</i> , 2022, 24, 867-870.	7.1	3
197	Multiparametric Cardiac Magnetic Resonance Imaging Detects Altered Myocardial Tissue and Function in Heart Transplantation Recipients Monitored for Cardiac Allograft Vasculopathy. <i>Journal of Cardiovascular Imaging</i> , 2022, 30, 263.	0.7	3
198	Why Continuity of STEM-Medicine Participation Matters: Exploring a Culture of Transformation and the Optimization of College Socialization. <i>Journal of Advanced Academics</i> , 2022, 33, 433-468.	1.1	3

#	ARTICLE	IF	CITATIONS
199	Response by Hess et al to Letter Regarding Article, "Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Program" Circulation, 2017, 135, e22-e23.	1.6	2
200	The ICD and Shared Decision Making: Nothing Is Ever Easy. Journal of Cardiac Failure, 2017, 23, 800-801.	1.7	2
201	The TREAT Trial"Moving ST-Elevation Myocardial Infarction Care Forward, With More to Do. JAMA Cardiology, 2018, 3, 399.	6.1	2
202	Is Heart Failure Inherited?. JAMA Cardiology, 2018, 3, 710.	6.1	2
203	Donor and Recipient Characteristics in Heart Transplantation Are Associated with Altered Myocardial Tissue Structure and Cardiac Function. Radiology: Cardiothoracic Imaging, 2019, 1, e190009.	2.5	2
204	Cancer therapy and the heart; the necessity to calibrate risk. European Journal of Heart Failure, 2020, 22, 1961-1965.	7.1	2
205	Explanation for the Corrections for the Study of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019. JAMA Cardiology, 2020, 5, 1308.	6.1	2
206	Anticipating a New Era in Heart Transplantation. JAMA Cardiology, 2020, 5, 625.	6.1	2
207	Heart Failure With Preserved Ejection Fraction and Obesity. JACC: Case Reports, 2020, 2, 28-32.	0.6	2
208	Association of cigarette smoking and adverse events in left ventricular assist device patients. International Journal of Artificial Organs, 2021, 44, 181-187.	1.4	2
209	Propensity Score-Matched Comparison of Right Ventricular Strain in Women and Men Before and After Left Ventricular Assist Device Implantation. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2022, 17, 102-110.	0.9	2
210	The challenges of data safety monitoring for a pragmatic study: Lessons from the ADAPTABLE study. Contemporary Clinical Trials, 2022, 115, 106732.	1.8	2
211	Stroke prevention in heart failure and sinus rhythm: where do we go from here?. European Journal of Heart Failure, 2016, 18, 1267-1269.	7.1	1
212	Does Guideline-Directed Medical Therapy for Heart Failure Offer Benefits After LVAD Placement?"A Call for a Randomized Clinical Trial. JAMA Cardiology, 2020, 5, 183.	6.1	1
213	The Use of Sacubitril/Valsartan for Hospitalized Heart Failure"Why Do We Care About Cost and Value?. JAMA Cardiology, 2020, 5, 1244.	6.1	1
214	Evaluating Biventricular Myocardial Velocity and Interventricular Dyssynchrony in Adult Patients During the First Year After Heart Transplantation. Journal of Magnetic Resonance Imaging, 2020, 52, 920-929.	3.4	1
215	To be, or not to be BAME, in the time of COVID-19: does it matter?. Heart, 2021, 107, 692-693.	2.9	1
216	Equity and the JAMA Network. JAMA Health Forum, 2021, 2, e211638.	2.2	1

#	ARTICLE	IF	CITATIONS
217	Rationale and Design of a Pharmacist-led Intervention for the Risk-Based Prevention of Heart Failure: The FIT-HF Pilot Study. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 785109.	2.4	1
218	Cardiovascular disease outcomes: priorities today, priorities tomorrow for research and community health. <i>Ethnicity and Disease</i> , 2012, 22, S1-7-12.	2.3	1
219	Distribution of 10- and 30-Year Predicted Risks for Heart Failure in the US Population: National Health and Nutrition Examination Surveys 2015 to 2018. <i>Circulation: Heart Failure</i> , 2022, , CIRCHEARTFAILURE121009351.	3.9	1
220	Who Is at Risk for Heart Failure?. <i>JAMA Cardiology</i> , 2022, , .	6.1	1
221	Resident Physician Wellness Postpandemic. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 2077.	7.4	1
222	In Search of a Solution From theÂSTICHÂTrialâ—. <i>Journal of the American College of Cardiology</i> , 2014, 64, 562-564.	2.8	0
223	Safety vs Efficacy of Lowering Blood Pressureâ€”Reply. <i>JAMA Cardiology</i> , 2017, 2, 1400.	6.1	0
224	Author Relationships With Industry. <i>JAMA Cardiology</i> , 2017, 2, 1181.	6.1	0
225	Addressing Cardiovascular Disease Disparitiesâ€”Are We Getting Closer to the Truth?. <i>JAMA Cardiology</i> , 2018, 3, 748.	6.1	0
226	HeartÂFailure Management UnderÂPressure. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3064-3066.	2.8	0
227	Failure Is Not an Option. <i>JACC: Heart Failure</i> , 2019, 7, 558-560.	4.1	0
228	The Critical Need for Process Improvement in Heart Failure. <i>Heart Failure Clinics</i> , 2020, 16, xiii-xv.	2.1	0
229	Distribution and Correlates of Incident Heart Failure Risk in South Asian Americans: The MASALA Study. <i>Journal of Cardiac Failure</i> , 2021, 27, 1214-1221.	1.7	0
230	Race Bias in Transcatheter Aortic Valve Replacement. <i>JAMA Cardiology</i> , 2022, 7, 158.	6.1	0
231	Association of readmission penalty amount with subsequent 30-day risk standardized readmission and mortality rates among patients hospitalized with heart failure: An analysis of get with the guidelines â€œ heart failure participating centers. <i>American Heart Journal</i> , 2022, 246, 1-11.	2.7	0
232	Title is missing!. , 2020, 15, e0240567.		0
233	Title is missing!. , 2020, 15, e0240567.		0
234	Title is missing!. , 2020, 15, e0240567.		0

#	ARTICLE	IF	CITATIONS
235	Title is missing!. , 2020, 15, e0240567.		0
236	Reducing disparities in cardiovascular health in African Americans through integrated cardiovascular sleep care in outpatient setting. SLEEP Advances, 2022, 3, .	0.2	0
237	Contemporary Trends and Comparison of Racial Differences in Hospitalizations of Adults With Congenital Heart Disease. American Journal of Cardiology, 2022, , .	1.6	0